

Efficacy of Mupirocin Ointment in Eradication of *Staphylococcus aureus* Nasal Carriage in Intensive Care Unit Staff and Patients

Abolfazl Khandandel (PhD Candidate)

Department of Microbiology, 5th Azar Hospital, Golstan University of Medical Sciences, Gorgan, Iran

Ania Ahani Azari (PhD)

Department of Microbiology, Islamic Azad University, Gorgan branch, Gorgan, Iran

Aylar Jamali (PhD)

Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Ezzat Allah Ghaemi (PhD)

Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Corresponding author: Abolfazl Khandandel

Tel: +98-174420651

Email: ab.khandandel@gmail.com

Address: Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Received : 29 Jan 2018

Revised: 02 Apr 2018

Accepted: 08 Apr 2018

ABSTRACT

Background and Objectives: *Staphylococcus aureus* is one of the most common causes of morbidity and mortality among intensive care unit (ICU) patients. Nasal carriage is one of the main routes of *S. aureus* transmission between hospital personnel and patients. The objective of this study was to evaluate the efficacy of mupirocin ointment in eradication of nasal carriage of *S. aureus* in the ICU staff and patients of Panje-Azar hospital in Gorgan, Iran.

Methods: In the first three months of the study (January to March), the prevalence of *S. aureus* among ICU patients was determined by routine microbiological and biochemical testing. Nasal samples were taken from ICU staff and all patients recently admitted to the ICU. Mupirocin nasal ointment (2%) was applied for treatment of *S. aureus* nasal carriers. Post-treatment sampling was done after five weeks. During the next three months, the presence of *S. aureus* and rate of resistance to methicillin was evaluated in new patients admitted to the ICU using the method used previously.

Results: Of 60 samples from the ICU staff, seven (11.7%) samples were positive for *S. aureus*. Moreover, of 240 samples from the ICU patients, two samples were found as *S. aureus*-positive. Of the nine *S. aureus*-positive isolates, only two (22.2%) were methicillin-resistant *S. aureus* (MRSA). In the pre-intervention sampling, only five samples (2.8%) were identified as *S. aureus*, two of which were MRSA. However, treatment with mupirocin ointment eradicated nasal carriage of *S. aureus* and no isolate was found after the intervention.

Conclusion: Our finding showed that mupirocin nasal ointment is highly effective in eradication of *S. aureus* nasal carriage and subsequently contribute to reduction in frequency of nosocomial infections in the ICU.

Keywords: Intensive Care Units, Mupirocin, Nasal, *Staphylococcus aureus*.

INTRODUCTION

Hospital-acquired infection is a global health problem associated with numerous factors. The etiological agents of these infections vary widely among different countries, but since 1980s, gram-positive bacteria especially *Staphylococcus aureus* have been considered as the main causative agent for nosocomial infections (1). The habitat of *S. aureus* is the anterior nasal canal and about 20% of the human population is thought to be carriers of this microorganism (2). The colonization rate of *S. aureus* in hospital staff is relatively higher than that in other individuals (3). These individuals are in constant contact with patients in different wards, which might consequently affect the progression of infection in the patients (1). The pathogenesis of *S. aureus* and its ability to acquire antimicrobial resistance have made this organism a major problem for hospitals and medical staff (3). *S. aureus* causes a wide range of infections including bacteremia, septicemia, pneumonia as well as skin, soft tissue and bone infections (4). Mupirocin is an ointment used for controlling staphylococcal infections in healthy carriers by inhibiting synthesis of isoleucyl-tRNA in the bacteria (5). Twice daily administration of mupirocin nasal ointment (2%) for five days is the most effective treatment for methicillin-resistant *S. aureus* (MRSA) carriage. MRSA strains are important nosocomial pathogens that can cause potentially deadly diseases. The treatment of infections caused by MRSA strains has been challenging because of multiple-drug resistance (6). Although vancomycin has been known as the antibiotic of choice for the treatment of infections caused by MRSA strains, studies from different parts of the world have recently reported the emergence of vancomycin-intermediate *S. aureus* (VISA) strains. The pathogenesis of MRSA and its increasing rate of resistance to antibiotics might prolong hospital stay, distress the patients and increase treatment costs. Hence, it is essential to take necessary measures for the control and prevention of MRSA infections (7). Since these microorganisms can easily spread in the hospital environment through respiratory secretions and contaminated hands, the most effective method of prevention is screening of nasal carriers among medical staff. Presence of *S. aureus* in the intensive care units (ICUs) is

of great importance due to use of invasive devices, prolonged hospital stay, weakened immune system, and frequent consumption of antibiotics (1). This study aimed to determine the efficiency of mupirocin ointment in eradication of *S. aureus* nasal carriage among the ICU staff and patients of Panje-azar hospital in Gorgan, Iran.

MATERIAL AND METHODS

This interventional study was performed on ICU staff and patients of Panje-azar teaching hospital during January-October 2014. The study received approval from the ethics committee of Golestan University of Medical Sciences (code: 509299302188). After obtaining necessary permission from the hospital authorities and written consent from the staff and family of patients, microbial culture of all samples from ICU patients were examined in the first three months of the study (January to March). Overall, 180 clinical samples were collected and cultured from 120 patients within 48 hours of admission to the hospital. Demographic data were recorded and studied for each patient. Samples found positive for *S. aureus* were recorded. *S. aureus* strains were detected by culture on mannitol salt agar and blood agar as well as biochemical testing according to standard guidelines (8). In the next two months (April and May), sampling was done with sterile nasal swabs from 60 personnel working in the hospital ICU and new patients admitted in the last 24 hours. Positive cultures for *S. aureus* were treated with mupirocin ointment (2%) for five days according to the instructions (5). To ensure about the eradication of *S. aureus* carriage, sampling was done after five weeks from the individuals treated with mupirocin and the patients who were admitted to the hospital since April 2014. Methicillin resistance was examined by disk diffusion method using cefoxitin disk (30µg, Himedia Co.) according to the Clinical and Laboratory Standards Institute guidelines (9) and using polymerase chain reaction (PCR) for presence of *mecA* gene as described by Louie et al (10). The following *MecA* primer sequences (CinnaGen Co., Iran) were used for the PCR experiment: Forward: TCCAGATTACAACCTTCACCAGG, Reverse: CCACTTCATATCTTGTAACG.

In the next three months (June to August), all cultures requested by the physician for the 120 ICU patients were examined and the results were recorded. The prevalence of *S. aureus* was determined in different periods and was later compared using chi-square test. P-values less than 0.05 were considered as statistically significant.

RESULTS

The most common reasons for hospital admission were car accidents (48.3%) and falling accident (10%). Level of consciousness in most patients was between 6 and 10 based on the Glasgow Coma Scale. All patients were using urinary and venous catheters (Table1). Of 180 samples collected, 97 samples (53.9%) were culture-positive, which were mostly related to chest tubes (40 cases) and blood samples (20 cases) (Table 2). Coagulase-negative staphylococci (16 cases), enterococci (15 cases), *Escherichia* (11 cases) and yeast (11 cases) were the most common organisms isolated. Of the 180 cultured samples from ICU patients in the first stage, *S. aureus* was isolated from five cases (2.8%, 2 men and 3 women), two of which were identified as MRSA (Figure 1). One case was an 18-year-old woman who was admitted to the ICU because of suicide attempt and died after 23 days. The second case was a 23-year-old woman who was hospitalized in the ICU due to a car accident (head injury) and died after 18 days. In this case, three samples were cultured and *S. aureus* was isolated in the sputum sample taken on the second day of hospitalization. The third case was a 29-year-old man who was admitted to the hospital due to leg fracture and was discharged after 11 days. For this patient, three blood samples were taken and cultured, and *S. aureus* was isolated on the fourth day. The next case was a

50-year-old woman who was hospitalized due to cardiac arrest and was discharged after 20 days. During her stay, four samples were cultured and *S. aureus* was isolated from the sputum culture on the tenth day. The fifth case was a 62-year-old man who was admitted to the hospital due to a falling accident, and was discharged after 10 days. In this case, two samples were cultured and MRSA was isolated from the chest tube sample taken on the tenth day.

Of the 60 nasal swab samples taken from the ICU staff, *S. aureus* was isolated only in seven samples (11.7%), two of which (22.2%) were identified as MRSA. Of the 120 nasal samples taken from the patients at admission, only two cases (1.6%) were identified as *S. aureus* but none was MRSA strain. Treatment with mupirocin eradicated *S. aureus* in all five carriers, as the post-treatment culture from the nasal carriers was negative after five weeks. However, the post-treatment culture was not performed for two patients because they had been discharged before the end of the fifth week. In the next stage of the study, the samples were taken from the patients three months after the intervention. Overall, 146 clinical samples (85 from men) were cultured and examined, which were mostly related to blood (11 specimens), urine (10 specimens) and chest tube (6 specimens) (Table 2). The culture was positive for 35 cases (23.97%). *Enterococcus*, coagulase-negative *Staphylococcus* and yeast were the most common isolated microorganisms from the ICU patients. *S. aureus* was not isolated from any of the samples. There was no significant difference between the pre- and post-intervention characteristics of the patients in the two groups. As shown in table 2, the treatment with mupirocin significantly reduced the frequency of *Staphylococcus*.

Figure1- Results of PCR for presence of MRSA strains. Column M: 1 Kb DNA ladder, C-: negative control (no DNA), C+: positive control, Columns 1-5: samples




Table 1- Characteristics of the subjects before and after the intervention

Characteristic	Before intervention	After intervention	P-value
Number of patients	120	120	0.9
Mean age (years)	45.5±20.3	44.1±23.4	0.7
Number of males	73 patients (60.8%)	85 patients (70.8%)	0.07
Average level of consciousness (6-10)	53 patients	66 patients	0.2
Use of invasive devices and prostheses			
NG tube	81	83	0.2
Ventilator	81	83	0.4
Endotracheal tube	81	83	0.5

Table 2- Efficacy of mupirocin ointment in eradication of *S. aureus* nasal carriage in 120 ICU patients

Characteristic	Before the intervention	After the intervention	P-value
Number of patients	120	120	0.9
Frequency of specimens			0.006
Urine	14	10	
Blood	20	11	
NG tube	40	6	
Others	23	8	
Frequency of positive cultures	97 (54%)	35 (24%)	0.002
Frequency of <i>S. aureus</i>	5 (4.2%)	0	0.002
Other bacteria			
<i>Enterococcus</i>	15	8	
Coagulase-negative <i>Staphylococcus</i>	16	6	
Yeast	11	6	
<i>Escherichia</i>	11	5	
<i>Streptococcus sp.</i>	8	5	
<i>Enterobacter</i>	9	3	
Others	22	2	
Total	92	35	

DISCUSSION

In the present study, the initial frequency of *S. aureus* nasal carriage was 11.7% among the ICU staff, 3.3% of which were identified as MRSA strain. In study of Rahimi-Alang et al. on healthcare workers in Gorgan, the frequency of *S. aureus* and MRSA nasal carriage was 24% and 3%, respectively (11). In study of Ruiz et al. in Ecuador, the prevalence of nasal carriage of MRSA among ICU staff was 2.4% (12). In some studies, the frequency of nasal carriage of *S. aureus* among hospital staff has been reported to be ranging between 11.9% and 33.28% (13-16). However, in a study in Iran, the prevalence of MRSA nasal carriage among a hospital's staff was 5.3% (17). Before the intervention, of the 120 ICU patients, only five patients had hospital

infection caused by *S. aureus*. This highlights that the infection control in the ICU has been satisfactory. Moreover, *S. aureus* was completely eradicated after the treatment with mupirocin nasal ointment. Two similar studies found the eradication rate of mupirocin to be 89.5% and 83.5% (18, 19). A study claimed that 91% eradication rate could be achieved with twice-daily administration of mupirocin for five days (20). Contrary to the previous studies, we completely eradicated nasal carriage of *S. aureus* using mupirocin ointment. The intervention was also successful in reducing the incidence of infection with *S. aureus* and other bacteria in the ICU. Of 120 patients admitted to the ICU during the three-month assessment, 72 patients had at least one

positive culture, while after the intervention, only 30 cases had positive culture results. This can be attributed to the greater hand hygiene adherence and better control of infection in the ICU. Our findings revealed that the prevalence of nasal carriage of *S. aureus* among ICU staff and patients was lower than that reported by other studies in Iran. Generally, the low prevalence of carriers in the ICU could be associated with the low number of nursing staff and the restrictions in this unit. Furthermore, no *S. aureus* was isolated after the treatment of the patients with mupirocin nasal ointment, indicating the high efficacy of the antibiotic in eradication of *S. aureus* carriage.

CONCLUSION

Compared to previous studies in Iran, the

REFERENCES

- Silva EC, Antas Md, Monteiro B Neto A, Rabelo MA, Melo FL, et al. *Prevalence and Risk Factors for Staphylococcus aureus in Health-Care Workers at a University Hospital of Recife-PE*. Braz J Infect Dis. 2008; 12(6): 504-8.
- Vinodhkumaradithyaa A, Uma A, Shirivasan M, Ananthalakshmi I, Nallasivam P, Thirumalaikolundusubramanian P. *Nasal Carriage of Methicillin-Resistant Staphylococcus aureus among Surgical Unit Staff*. Jpn J Infect Dis 2013; 62(3): 228-229.
- de Carvalho MJ, Pimenta FC, Hayashida M, Gir E, da Silva AM, Barbosa CP, et al. *Prevalence of methicillin-resistant and methicillin-susceptible S. aureus in the Saliva of health professionals*. CLINICS. 2009; 64(4): 295-302.
- Treacle A, Thom KA, Furuno P. *Bacterial contamination of health care workers white coats*. Am J Infect Control. 2009; 37(2): 101-105. doi: 10.1016/j.ajic.2008.03.009.
- Bertman G, Katzung MD. *Basic Pharmacology*. New York: Mc Grow-Hill. 2016; 793-802.
- Ojulong J, Mwambu TP, Jolobo M, Agwu E, Bwanga F, Najjuka C, et al. *Prevalence of Methicillin Resistant Staphylococcus aureus (MRSA) Among Isolates from Surgical site Infections in Mulago Hospital, Kampala, Uganda*. The Internet Journal of Infectious Disease. 2009; 7.
- Saderi H, Owlia P, Maleki Z, Habibi M, Rahmati N. *Susceptibility to Vancomycin in Staphylococcus aureus Isolated From Patients of Four University-Affiliated Hospitals in Tehran*. Iranian Journal of Pathology. 2008; 3: 161-166.
- Forbe BA, Sahm DF, Weissfeld AS. *Bailey & Scotts Diagnostic Microbiology*. 14th ed. Mosby, New York. 2015; 172-213.
- CLSI: Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing; 24th informational supplement*. CLSI, Wayne, PA. M100-S21 2017; 31(1). 8: 161-165.
- Louie L, Goodfellow J, Mathiew P, Glatt A, Louie M, Simor A. *Rapid detection of Methicillin resistant Staphylococci from blood culture bottles by using a multiplex PCR assay*. J Clin Microbiol. 2002; 40(8): 2786-2790.
- Rahimi-Alang S, Asmar M, Cheraghali F, Yazarlou S, Amini A, Shakeri F, et al. *Frequency of methicillin resistant Staphylococcus aureus in healthcare workers in Gorgan*. Zahedan J Res Med Sci (Tabib-e-shargh). 2011; 13(1): 17-22. [Persian]
- Ruiz A, Mora M, Zurita C, Larco D, Toapanta Y, Zurita J. *Prevalence of methicillin-resistant Staphylococcus aureus among health care workers of intensive care units in Ecuador*. J Infect Dev Ctries. 2014; 8(1): 116-9.
- Khalili M, Moshref M, Sharifi M, Sadeh M, Szamand A. *Prevalence of Staphylococcus aureus (SA) and Methicillin resistant Staphylococcus aureus (MRSA) in personnel of Operation room of Shahid Sadoughi hospital, Yazd, Iran*. Payavard Salamat. 2013; 6(5): 392-402. [Persian]
- Shibabaw A, Abebe T, Mihret A. *Nasal carriage rate of methicillin resistant Staphylococcus aureus among dessie referral hospital health care workers; dessie, Northeast Ethiopia*. Antimicrob Resist Infect Control. 2013; 2: 25. doi: 10.1186/2047-2994-2-25.
- Serag-Eldin AS, Amany TA, Noha GA, Mohamed EAA. *Clinical and microbiological effect of linezolid on Methicillin resistant Staphylococcus aureus (MRSA) colonization in healthcare workers in Egypt*. Middle East J Sci Res. 2013; 15(10): 1440-9.
- Mansouri Ghiasi MA, Nasrollahi Omran A, Hashemi M, RajabZade Kanafi P, Jahangiri Rad M. *The prevalence of antibiotic resistance pattern of Staphylococcus aureus isolated from nasal carriage of surgical ward's staff in Shahid Rajaei hospital of Tonekabon, Iran*. Medical Laboratory Journal. 2013; 7(1): 35-39. [Persian]
- Askarian M, Zeinalzadeh A, Japoni A, Alborzi A, Memish ZA. *Prevalence of nasal carriage of methicillin-resistant Staphylococcus aureus and its antibiotic susceptibility pattern in healthcare workers at Namazi Hospital, Shiraz, Iran*. International Journal of Infectious Diseases. 2009; 13(5):e241-7. doi: 10.1016/j.ijid.2008.11.026.
- Sarmadian, h. Dydgr, f. Abtahi, h.2008. *Comparison of mupirocin nasal cream effect of single-dose oral ciprofloxacin in the treatment of recurrent nasal carriers of Staphylococcus aureus in personnel in Valiasr*. Journal of Medical Sciences, 2004: Vol. 11, No. 1, pp, 40-44.
- Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, Bogaers-Hofman D, de Baere GA, Stuurman A, et al. *Surgical Site Infections in Orthopedic Surgery: The Effect of Mupirocin Nasal Ointment in a Double-Blind, Randomized, Placebo-Controlled Study*. Clin Infect Dis. 2002; 35(4): 353-8.
- Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP Jr, et al. *Elimination of S. aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment*. Clin Infect Dis. 1993; 17(3): 466-74.

ACKNOWLEDGMENTS

The study has been financially supported by the Infectious Disease and Medical Laboratory Sciences Research Centers of the Golestan University of Medical Sciences, Iran.

CONFLICT OF INTEREST

The authors declare no conflict of interest.